Auxilium buys a privately held urology company as its base business weakens.
As Vertex shares surge on positive drug news, the company's CFO sells a massive stake.
Celsion won't let a failed liver cancer therapy stand in the way of executives collecting paychecks.
New hepatitis C data released Tuesday doesn't change the dynamics of the race towards all-oral therapies.
Linzess sales of $4.5 million fall well short of Wall Street expectations.
Dendreon investor Brad Loncar is tweeting from today's Dendreon annual shareholder meeting.
The FDA hasn't granted Vascepa three years of market exclusivity, making it easier for generics to undercut sales.
Vertex will generate billions of dollars from its dominate cystic fibrosis drug franchise.
Cologuard is accurate enough to pass muster with FDA but investors were looking for more.
Alkermes plans to move ALKS 5461 into phase III studies following positive mid-stage results.
MannKind is conducting a large, two-year safety study of its inhaled, fast-acting insulin but doesn't talk about it. Why?
Vivus' Qsymia will now be available at retail pharmacies.
Acorda is seeking to expand the use of Ampyra beyond multiple sclerosis.
Acadia will no longer need to run a confirmatory study of pimavanserin before seeking approval.
A favorable FDA ruling on Qsymia's distribution is not enough for First Manhattan.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV